2-[(叠氮乙酰基)氨基]-2-脱氧-D-吡喃半乳糖 | 869186-83-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-[(叠氮乙酰基)氨基]-2-脱氧-D-吡喃半乳糖
• 中文别名: 2-[(2-叠氮基乙酰基)氨基]-2-脱氧-D-半乳糖
• 英文名称: 2-[(Azidoacetyl)amino]-2-deoxy-D-galactose
• 英文别名: 2-azido-N-[(2R,3R,4R,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]acetamide
• CAS: 869186-83-4
• 化学式: C8H14N4O6
• 分子量: 262.22
• InChiKey: SBNIXWHTKPFIQR-LAHCRNKXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  141
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] PROCESS FOR THE CYCLOADDITION OF A HALOGENATED 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE<br/>[FR] PROCÉDÉ DE CYCLOADDITION D'UN COMPOSÉ 1,3-DIPPOLE HALOGÉNÉ AVEC UN (HÉTÉRO)CYCLOALKYNE
  申请人：SYNAFFIX BV

  公开号：WO2015112016A1

  公开（公告）日：2015-07-30

  The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Formula (1) is a (hetero)cyclooctyne. The invention also relates to the cycloaddition products obtainable by the process according to the invention. The invention further relates to halogenated aliphatic 1,3- dipole compounds, in particular tohalogenated aliphatic 1,3-dipole compounds comprising N-acetylgalactosamine-UDP (GalNAc-UDP),and to halogenated 1,3- dipole compounds comprising (peracylated) N-acetylglucosamine(GlcNAc), N- acetylgalactosamine(GalNAc), N-acetylmannosamine(ManNAc)and N- acetylneuraminic acid(NeuNAc).

  本发明涉及一种环加成过程，包括将卤代脂肪1,3-二极化合物与按照式（1）反应的（杂）环烯烃化合物进行反应的步骤。优选，按照式（1）的（杂）环烯烃化合物是（杂）环辛烯。该发明还涉及根据本发明的方法获得的环加成产物。此外，该发明还涉及卤代脂肪1,3-二极化合物，特别是包括N-乙酰半乳糖氨基葡萄糖醛酸-UDP（GalNAc-UDP）的卤代脂肪1,3-二极化合物，以及包括（过酰化的）N-乙酰葡萄糖胺（GlcNAc）、N-乙酰半乳糖氨基葡萄糖醛酸（GalNAc）、N-乙酰甘露糖氨基葡萄糖醛酸（ManNAc）和N-乙酰神经酸（NeuNAc）的卤代1,3-二极化合物。
• [EN] CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS<br/>[FR] PROCÉDÉS CHIMIO-ENZYMATIQUES POUR SYNTHÉTISER DES ANALOGUES DE LA MOÉNOMYCINE
  申请人：HARVARD COLLEGE

  公开号：WO2013152279A1

  公开（公告）日：2013-10-10

  The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).

  本发明提供了合成式(I)的莫诺霉素类似物的方法。本发明还提供了包含式(I)化合物的组合物和用于合成式(I)化合物的试剂盒。
• PROCESS FOR THE CYCLOADDITION OF A HETERO(ARYL) 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE
  申请人：SYNAFFIX B.V.

  公开号：US20170002012A1

  公开（公告）日：2017-01-05

  A process is provided, comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein the (hetero)aryl 1,3-dipole compound comprises a 1,3-dipole functional group bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein: (i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises a substituent (ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1). The invention also relates to the products obtainable by the process according to the invention.

  提供一种方法，包括将（杂）芳基1,3-二极化合物与（杂）环炔反应，其中（杂）芳基1,3-二极化合物包括与（杂）芳基结合的1,3-二级极功能基团，并且（杂）芳基1,3-二极化合物是（杂）芳基叠氮化物或（杂）芳基重氮化合物；其中：（i）（杂）芳基1,3-二极化合物的（杂）芳基包括一个取代基（ii）（杂）芳基1,3-二极化合物的（杂）芳基是一个电子贫富（杂）芳基，并且（杂）环炔是根据式（1）的（杂）环辛烯或（杂）环壬炔。该发明还涉及根据该发明的方法获得的产品。
• PROCESS FOR THE CYCLOADDITION OF A HALOGENATED 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE
  申请人：SYNAFFIX B.V.

  公开号：US20170008858A1

  公开（公告）日：2017-01-12

  The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Formula (1) is a (hetero)cyclooctyne. The invention also relates to the cycloaddition products obtainable by the process according to the invention. The invention further relates to halogenated aliphatic 1,3-dipole compounds, in particular to halogenated aliphatic 1,3-dipole compounds comprising N-acetylgalactosamine-UDP (GalNAc-UDP), and to halogenated 1,3-dipole compounds comprising (peracylated) N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), N-acetylmannosamine (ManNAc) and N-acetyl neuraminic acid (NeuNAc).

  本发明涉及一种环加成过程，包括以下步骤：将卤代脂肪1,3-二极化合物与根据式（1）的（杂）环烷炔发生反应。优选，根据式（1）的（杂）环烷炔是（杂）环辛炔。本发明还涉及根据本发明的过程获得的环加成产物。本发明还涉及卤代脂肪1,3-二极化合物，特别是包含N-乙酰半乳糖氨基葡萄糖醛酸-UDP（GalNAc-UDP）的卤代脂肪1,3-二极化合物，以及包含（过酰化的）N-乙酰葡萄糖胺（GlcNAc）、N-乙酰半乳糖氨基（GalNAc）、N-乙酰甘露糖氨基（ManNAc）和N-乙酰神经酸（NeuNAc）的卤代1,3-二极化合物。
• [EN] IMPROVED METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES<br/>[FR] PROCÉDÉS AMÉLIORÉS D'IMAGERIE AVEC DES MOLÉCULES MARQUÉES AU GA-68
  申请人：IMMUNOMEDICS INC

  公开号：WO2017007807A1

  公开（公告）日：2017-01-12

  The present application discloses compositions and methods of use of 68Ga labeled molecules. Preferably, the 68Ga is attached to a peptide targetable construct and is used in a pretargeting technique with a bispecific antibody (bsAb). The bsAb comprises at least one binding site for a disease-associated antigen, such as a tumor-associated antigen, and at least one binding site for a hapten on the targetable construct. Exemplary haptens include In-DTPA and HSG. More preferably, the bsAb is administered about 24-30 hours before the targetable construct, and detection by PET imaging occurs about 1-2 hours after the targetable construct is administered. The methods and compositions are suitable for detection, diagnosis and/or imaging of various diseases, such as cancer or infectious disease.

  本申请公开了68Ga标记分子的组成和使用方法。优选地，68Ga附着在可靶向的肽构造物上，并与双特异性抗体（bsAb）一起用于一种预靶向技术。该bsAb至少包括一个与疾病相关抗原（如肿瘤相关抗原）结合的结合位点，以及一个与可靶向构造物上的半抗原结合的结合位点。示例半抗原包括In-DTPA和HSG。更优选地，bsAb在可靶向构造物之前约24-30小时给予，并在可靶向构造物给予后约1-2小时进行PET成像检测。这些方法和组成适用于检测、诊断和/或成像各种疾病，如癌症或传染病。